FDA Renews Psychopharmacologic Drugs Advisory Committee
Published Date: 5/29/2026
Notice
Summary
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for two more years, keeping it active until June 4, 2028. This committee helps make sure psychiatric drugs are safe and effective, affecting drug makers, doctors, and patients. No new costs or big changes, just a smooth continuation of expert advice to keep mental health treatments on track.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Clozapine REMS Participation Changed (2024)
The committee's 2024 recommendations informed the FDA's decision to no longer expect prescribers, pharmacies, and patients to participate in the Clozapine REMS program or to report absolute neutrophil count (ANC) blood test results before pharmacies dispense clozapine. That change reduced procedural obligations for prescribers, pharmacies, and patients related to clozapine access.
Psychiatric Advisory Panel Renewed
The FDA renewed the Psychopharmacologic Drugs Advisory Committee for an additional two years, with the new charter in effect until June 4, 2028. The committee will continue to provide expert advice aimed at ensuring psychiatric drugs are safe and effective, affecting drug makers, prescribers, and patients; the notice states there are no new costs or major changes with this renewal.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10734 — Content of Human Factors Information in Medical Device Marketing Submissions; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just released new guidance to help medical device makers include the right human factors info in their marketing submissions. This makes the review process faster and clearer for everyone involved. If you make or review medical devices, get ready to follow these updated steps starting now—saving time and possibly money!
2026-10675 — Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.
2026-10703 — Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application; Guidance for Industry; Availability
The FDA just released final guidance to help drug companies prove their generic drugs work just like the original ones by using bioequivalence studies. This affects anyone submitting or updating abbreviated new drug applications (ANDAs) and aims to make the approval process clearer and smoother. Companies should review these new rules now to avoid delays and extra costs when getting their generics to market.
2026-10614 — Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove three harmful solvents—ethylene dichloride, methylene chloride, and trichloroethylene—from color additive rules. This change affects companies using these solvents in color additives and aims to make products safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any final decisions.
2026-10615 — Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove four harmful solvents—benzene, ethylene dichloride, methylene chloride, and trichloroethylene—from food additive rules. This change affects food makers who use these solvents and aims to make our food safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any costly changes happen.
2026-10603 — Challenges and Solutions in Lot-Level Food Traceability; Public Meeting and Request for Comments
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!
Previous / Next Documents
Previous: 2026-10673 — Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest
The U.S. International Trade Commission got a complaint from Caterpillar about some heavy machinery parts being imported and sold unfairly by Doosan Bobcat companies around the world. They want to stop these imports and sales while the case is reviewed, which could affect businesses and buyers soon. The public and other groups have a chance to share their thoughts before any decisions are made.
Next: 2026-10676 — Caribou-Targhee National Forest; Wyoming; Amendment to the 1997 Land Management Plan for the Targhee National Forest
The Forest Service is updating the 1997 Targhee National Forest Plan to allow the Grand Targhee ski resort to expand by changing how 694 acres of forest land are used. This affects local outdoor lovers and businesses by turning some protected areas into special recreation zones. People have 60 days to raise any concerns before the changes get final approval.